

# Controlled Clinical Trials

## DESIGN, METHODS, AND ANALYSIS

---

*Official Journal of the Society for Clinical Trials*

**Volume 24, Number 1, 2003**

### **Contents**

<b>Call for papers</b>	1
<b>Preface</b>	2
<b>Original articles</b>	
MICHAEL A. PROSCHAN, QING LIU, SALLY HUNSBERGER Practical midcourse sample size modification in clinical trials	4
Y.H. JOSHUA CHEN, DAVID L. DEMETS, K.K. GORDON LAN Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis	16
NEAL L. ODEN, DALE L. PHELPS, ON BEHALF OF THE STOP-ROP MULTICENTER STUDY GROUP Statistical issues related to early closure of STOP-ROP, a group-sequential trial	28
DEBORAH J. BOWEN, MARK THORNQUIST, KAREN ANDERSON, MATT BARNETT, CORINNE POWELL, GARY GOODMAN, GILBERT OMENN Stopping the active intervention: CARET	39
LETICIA DELGADO-HERRERA, DAN ANBAR A model for the interim analysis process: a case study	51
<b>Invited papers</b>	
KEITH WHEATLEY, DAVID CLAYTON Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization	66
JOSEPH F. COLLINS Data and safety monitoring board issues raised in the VA Status Epilepticus Study	71
MARIO CHEN-MOK, SHRIKANT I. BANGDIWALA, ROSALIE DOMINIK, MELISSA HAYS, BELINDA IRSULA, DAVID C. SOKAL Termination of a randomized controlled trial of two vasectomy techniques	78
DAVID W. HILLMAN, THOMAS A. LOUIS DSMB case study: decision making when a similar clinical trial is stopped early	85
ADELE M. KAPLAN GILPIN, JANET T. HOLBROOK, DOUGLAS A. JABS, CURTIS L. MEINERT, FOR THE STUDIES OF OCULAR COMPLICATIONS OF AIDS RESEARCH GROUP Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial	92
DAVID SCHEIFELE, BERNARD DUVAL, GASTON DE SERRES, DANUTA M. SKOWRONSKI Unique roles of a data and safety monitoring board in vaccine safety trials with compressed timelines and urgent implications	99
<b>Book review</b>	105
<b>List of reviewers</b>	107

## **Volume 24, Number 2, 2003**

### **Contents**

**Call for papers** 109

### **Original articles**

SAY-BENG TAN, Y.-F. ALEXANDER CHUNG, BEE-CHOO TAI,  
YIN-BUN CHEUNG, DAVID MACHIN

Elicitation of prior distributions for a phase III randomized controlled trial  
of adjuvant therapy with surgery for hepatocellular carcinoma 110

A. GREGORY DIRIENZO, VICTOR DEGRUTTOLA

Design and analysis of clinical trials with a bivariate failure time endpoint,  
with application to AIDS Clinical Trials Group Study A5142 122

HONGYU JIANG, RICK CHAPPELL, JASON P. FINE

Estimating the distribution of nonterminal event time in the presence of  
mortality or informative dropout 135

SUE-JANE WANG, H.M. JAMES HUNG

Assessing treatment efficacy in noninferiority trials 147

VANCE W. BERGER, AZADEH REZVANI, VANESSA A. MAKAREWICZ

Direct effect on validity of response run-in selection in clinical trials 156

JITENDRA GANJU, DEVAN V. MEHROTRA

Stratified experiments reexamined with emphasis on multicenter trials 167

ARTHUR A. STONE, SAUL SHIFFMAN, JOSEPH E. SCHWARTZ,

JOAN E. BRODERICK, MICHAEL R. HUFFORD

Patient compliance with paper and electronic diaries 182

**Book reviews** 200

### **Design papers**

WENDY DEMARK-WAHNEFRIED, MIRIAM C. MOREY, ELIZABETH C. CLIPP,  
CARL F. PIEPER, DENISE CLUTTER SNYDER, RICHARD SLOANE,  
HARVEY J. COHEN

Leading the Way in Exercise and Diet (Project LEAD): intervening to  
improve function among older breast and prostate cancer survivors 206

OLIVER M. BAUTISTA, JOHN W. KUSEK, LEROY M. NYBERG JR.,

JOHN D. MCCONNELL, RAYMOND P. BAIN, GARY MILLER,

E. DAVID CRAWFORD, STEVEN A. KAPLAN, STEPHEN A. SIHELNIK,

MICHAEL K. BRAWER, HEBERT LEPOR, FOR THE MTOPS RESEARCH GROUP

Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial 224

## **Volume 24, Number 3, 2003**

### **Contents**

### **Original articles**

WILLIAM BURMAN, PETER BREESE, STEPHEN WEIS, NAOMI BOCK,  
JOHN BERNARDO, ANDREW VERNON, AND THE TUBERCULOSIS  
TRIALS CONSORTIUM

The effects of local review on informed consent documents from a  
multicenter clinical trials consortium 245

ROBERT M. CALIFF, MICHAEL A. MORSE, JANET WITTES,  
STEVEN N. GOODMAN, DANIEL K. NELSON, DAVID L. DEMETS,  
R. PETER IAFRATE, JEREMY SUGARMAN

Toward protecting the safety of participants in clinical trials 256

NICOLA MILLS, JENNY L. DONOVAN, MONICA SMITH, ANN JACOBY, DAVID E. NEAL, FREDDIE C. HAMDY Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study	272
CHENGJIE XIONG, YAN YAN, MING JI Sample sizes for comparing means of two lifetime distributions with type II censored data: application in an aging intervention study	283
STEVEN E. FELDON, ROBERTA W. SCHERER, FRANK J. HOOPER, SHALOM KELMAN, ROBERT S. BAKER, ROBERT J. GRANADIER, GREGORY S. KOSMORSKY, STUART R. SEIFF, KAY DICKERSIN, FOR THE ISCHEMIC OPTIC NEUROPATHY DECOMPRESSION TRIAL RESEARCH GROUP Surgical quality assurance in the Ischemic Optic Neuropathy Decompression Trial (IONDT)	294
DAVID JARJOURA Crossing controls to treatment in repeated-measures trials	306
CHRISTOPHER H. SCHMID, MARCIA LANDA, TAZEEN H. JAFAR, IOANNIS GIATRAS, TAUQEER KARIM, MANOJ REDDY, PAUL C. STARK, ANDREW S. LEVEY, FOR THE ANGIOTENSIN-CONVERTING ENZYME INHIBITION IN PROGRESSIVE RENAL DISEASE (AIPRD) STUDY GROUP Constructing a database of individual clinical trials for longitudinal analysis	324
AL HALLSTROM, LAWRENCE FRIEDMAN, PABLO DENES, CARLOS RIZO-PATRON, MARY MORRIS, AND THE CAST AND AVID INVESTIGATORS Do arrhythmia patients improve survival by participating in randomized clinical trials? Observations from the Cardiac Arrhythmia Suppression Trial (CAST) and the Antiarrhythmics Versus Implantable Defibrillators Trial (AVID)	341
<b>Book review</b>	353

**Volume 24, Number 3S, 2003  
Supplement**

**Contents**

Letter from the President	1S
Calendar of Program	7S
Abstracts: Third Joint Meeting of the Society for Clinical Trials and the International Society for Clinical Biostatistics	43S
Author Index	241S

**Volume 24, Number 4, 2003**

**Contents**

**Original articles**

MITHAT GÖNEN Planning for subgroup analysis: a case study of treatment-marker interaction in metastatic colorectal cancer	355
---	-----



MAN-LAI TANG	
Matched-pair noninferiority trials using rate ratio: a comparison of current methods and sample size refinement	364
JAMES X. SONG, JAMES T. WASSELL	
Sample size for $K \times 2$ tables in equivalence studies using Cochran's statistic	378
REBECCA HOLMAN, CEES A.W. GLAS, ROB J. DE HAAN	
Power analysis in randomized clinical trials based on item response theory	390
LAURENCE S. MAGDER	
Simple approaches to assess the possible impact of missing outcome information on estimates of risk ratios, odds ratios, and risk differences	411
MARIE JACKSON, NANCY BERMAN, MARGARET HUBER, LINDA SNETSELAAR, IRIS GRANER, KATHRYN BOE, CAROLE MILAS, JILL SPIVAK, ROWAN T. CHLEBOWSKI	
Research staff turnover and participant adherence in the Women's Health Initiative	422
Letter to the editor	436
Book review	440
Design papers	
THE BENEDICT GROUP	
The BERgamo NEphrologic Diabetes Complications Trial (BENEDICT): design and baseline characteristics	442
GARY D. MILLER, W. JACK REJESKI, JEFF D. WILLIAMSON, TIMOTHY MORGAN, MARY ANN SEVICK, RICHARD F. LOESER, WALT H. ETtingER, STEPHEN P. MESSIER FOR THE ADAPT INVESTIGATORS	
The Arthritis, Diet and Activity Promotion Trial (ADAPT): design, rationale, and baseline results	462
TASSOS C. KYRIAKIDES, ABDEL BABIKER, JOEL SINGER, WILLIAM CAMERON, MARTIN T. SCHECHTER, MARK HOLODNIY, SHELDON T. BROWN, MIKE YOULE, BRIAN GAZZARD ON BEHALF OF THE OPTIMA STUDY TEAM	
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial	481

## Volume 24, Number 5, 2003

### Contents

#### Original articles

RAYMOND Q. MIGRINO, ERIC J. TOPOL	
A matter of life and death? The Heart Protection Study and protection of clinical trial participants	501
THEODORE G. KARRISON, DEZHENG HUO, RICK CHAPPELL	
A group sequential, response-adaptive design for randomized clinical trials	506
CAROLINE C. MORGAN	
Estimation following group-sequential response-adaptive clinical trials	523

LUKE B. CONNELLY	
Balancing the number and size of sites: an economic approach to the optimal design of cluster samples	544
MIYUKI KAWADO, SHIRO HINOTSU, YUTAKA MATSUYAMA, TAKUHIRO YAMAGUCHI, SHUJI HASHIMOTO, YASUO OHASHI	
A comparison of error detection rates between the reading aloud method and the double data entry method	560
MIKE R. SATHER, DENNIS W. RAISCH, CLAIR M. HAAKENSEN, JULIA M. BUCKELEW, JOHN R. FEUSSNER	
Promoting good clinical practices in the conduct of clinical trials: experiences in the Department of Veterans Affairs Cooperative Studies Program	570
<b>Commentary</b>	
SUSAN S. ELLENBERG	
Are all monitoring boundaries equally ethical?	585
<b>Book review</b>	589
<b>Design papers</b>	
KAY DICKERSIN, MALCOLM MUNRO, PATRICIA LANGENBERG, ROBERTA SCHERER, KEVIN D. FRICK, ANNE M. WEBER, ALAN JOHNS, JEFFREY F. PEIPERT, MELISSA CLARK, AND THE STOP-DUB RESEARCH GROUP	
Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB): design and methods	591
THE LOOK AHEAD RESEARCH GROUP	
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes	610
LINDA BRUBAKER, GEOFF CUNDIFF, PAUL FINE, INGRID NYGAARD, HOLLY RICHTER, ANTHONY VISCO, HALINA ZYCZYNSKI, MORTON B. BROWN, ANNE WEBER, FOR THE PELVIC FLOOR DISORDERS NETWORK	
A randomized trial of colpopexy and urinary reduction efforts (CARE): design and methods	629
J.M. STEPHENSON, A. OAKLEY, A.M. JOHNSON, S. FORREST, V. STRANGE, S. CHARLESTON, S. BLACK, A. COPAS, A. PETRUCKEVITCH, A. BABIKER	
A school-based randomized controlled trial of peer-led sex education in England	643
<b>Announcements</b>	659
<b>Program 2003 Errata</b>	665

## Volume 24, Number 6, 2003

### Contents

<b>Preface</b>	667
----------------	-----

### Original articles

THOMAS M. BRAUN, JOHN E. LEVINE, JAMES L.M. FERRARA	
Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM	669

KEVIN J. CARROLL	
On the use and utility of the Weibull model in the analysis of survival data	682
PHILIP P. BREITFELD, FRED ULLRICH, JAMES ANDERSON, WILLIAM M. CRIST	
Web-based decision support for clinical trial eligibility determination in an international clinical trials network	702
JEFFREY J. WALLINE, LISA A. JONES, DONALD O. MUTTI, KARLA ZADNIK	
Use of a run-in period to decrease loss to follow-up in the Contact Lens and Myopia Progression (CLAMP) study	711
<b>Invited papers</b>	
SHEILA SPRAGUE, PAMELA LEECE, MOHIT BHANDARI, PAUL TORNETTA, EMIL SCHEMITSCH, MARC F. SWINOTKOWSKI, ON BEHALF OF THE S.P.R.I.N.T. INVESTIGATORS	
Limiting loss to follow-up in a multicenter randomized trial in orthopedic surgery	719
JOSEPH F. COLLINS, CINDY L. HOWELL, R. ANNE HORNEY FOR THE DIGITALIS INVESTIGATION GROUP (DIG) INVESTIGATORS	
Determination of vital status at the end of the DIG trial	726
ANDREW J. VICKERS, ROB MCCARNEY	
Use of a single global assessment to reduce missing data in a clinical trial with follow-up at one year	731
<b>Design papers</b>	
CHRISTIAN C. APFEL, KARI KORTTILA, MONA ABDALLA, ANDREAS BIEDLER, PETER KRANKE, STUART J. POCOCK, N. ROEWER	
An International Multicenter Protocol to Assess the single and combined benefits of antiemetic interventions in a Controlled clinical Trial of a $2 \times 2 \times 2 \times 2 \times 2 \times 2$ factorial design (IMPACT)	736
MICHIEL L. BOTS, GREGORY W. EVANS, WARD RILEY, RUDY MEIJER, KAREN H. MCBRIDE, ELECTRA D. PASKETT, FRANS A. HELMOND, DIEDERICK E. GROBBEE, FOR THE OPAL INVESTIGATORS	
The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics	752
ROB BEANLANDS, GRAHAM NICHOL, TERRENCE D. RUDDY, ROBERT A. DEKEMP, PAUL HENDRY, DENNIS HUMEN, NORMAND RACINE, HEATHER ROSS, FRANCOIS BENARD, GEOFFREY COATES, ROBERT M. IWANOCHKO, ERNEST FALLEN, GEORGE WELLS, AND THE PARR-2 INVESTIGATORS	
Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods	776
THE CHILDREN'S AMALGAM TRIAL STUDY GROUP	
The Children's Amalgam Trial: design and methods	795
THE CTNS STUDY GROUP	
The Italian-American Clinical Trial of Nutritional Supplements and Age-Related Cataract (CTNS): design implications. CTNS report no. 1	815
<b>List of Reviewers</b>	831
<b>Volume 24 Author Index</b>	833
<b>Volume 24 Subject Index</b>	836
<b>Volume Contents</b>	845

**Volume 24, Number 6S, 2003  
Supplement**

**Contents**

List of contributors	267S
JOSEPH F. COLLINS, DEBRA EGAN, SALIM YUSUF, REKHA GARG, WILLIAM O. WILLIFORD, NANCY GELLER ON BEHALF OF THE DIG INVESTIGATORS Overview of the DIG trial	270S
WILLIAM O. WILLIFORD, JOSEPH F. COLLINS, ANNE HORNEY, GAIL KIRK, FRANCES MCSHERRY, ELIZABETH SPENCE, SUSAN STINNETT, CINDY L. HOWELL, REKHA GARG, DEBRA EGAN, SALIM YUSUF ON BEHALF OF THE DIG INVESTIGATORS The role of the data coordinating center in the DIG trial	278S
CAROL L. FYE, WILLIAM H. GAGNE, DENNIS W. RAISCH, MARK S. JONES, MIKE R. SATHER, SANDRA L. BUCHANAN, FRANCES R. CHACON, REKHA GARG, SALIM YUSUF, WILLIAM O. WILLIFORD ON BEHALF OF THE DIG INVESTIGATORS The role of the pharmacy coordinating center in the DIG trial	290S
JOSEPH F. COLLINS, SYLVIA MARTIN, ELEANOR KENT, CONNIE LIUNI, REKHA GARG, DEBRA EGAN ON BEHALF OF THE DIG INVESTIGATORS The use of regional coordinating centers in large clinical trials: the DIG trial	299S
JOSEPH F. COLLINS, REKHA GARG, KOON K. TEO, WILLIAM O. WILLIFORD, CINDY L. HOWELL ON BEHALF OF THE DIG INVESTIGATORS The role of the data coordinating center in the IRB review and approval process: the DIG trial experience	307S
DEBRA EGAN, NANCY GELLER, SALIM YUSUF, REKHA GARG, JOSEPH F. COLLINS, JAMES MATHEW, EDWARD PHILBIN ON BEHALF OF THE DIG INVESTIGATORS Lessons learned from the DIG trial	317S
Appendix	328S



